Skip to main content
. 2021 May 20;2021(5):CD013600. doi: 10.1002/14651858.CD013600.pub4

9. Serious adverse events (SAEs).

Study Number of participants Serious adverse events
CP group Control group
Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease
Agarwal 2020 227 in CP group and 224 in control group

  • 3 transfusion‐related SAEs: deaths could possibly be related to transfusion

 NR 
AlQahtani 2020 20 in CP group and 20 in control group NR NR
Avendano-Sola 2020 38 in CP group and 43 in control group 

  • 6 individuals with SAEs, included in Analysis 1.15

  • 7 individuals with SAEs, included in Analysis 1.15
Gharbharan 2020 43 in group and  43 in control group 

  • 0 individuals with serious transfusion‐related adverse events

 NR
Hamdy Salman 2020 15 in group and 15  in control group  NR NR
Horby 2021 5795 in group and 5763 in control group 

  • 13 individuals with transfusion‐related serious adverse reactions reported to SHOT:

    • 9 patients with pulmonary reactions (including 3 deaths possibly related to transfusion)

    • 4 patients with serious febrile, allergic or hypotensive reactions

 NR  
Li 2020 52 in CP group and 51 in control group NR
 
 
 		 NR
Ray 2020 40 in CP group and 40 in control group NR NR
Simonovich 2020 228 in CP group and 105 in control group

  • 54 individuals with SAEs, included in Analysis 1.15

  • 19 individuals with SAEs, included in Analysis 1.15
Convalescent plasma versus standard plasma for individuals with moderate to severe disease
Bajpai 2020 14 in CP group and 15 in control group NR NR
 
O’Donnell 2021 147 in CP group an 72 in control group

  • 39 individuals with SAEs, included in Analysis 2.5

  • 26 individuals with SAEs, included in Analysis 2.5
Convalescent plasma (no comparison) for individuals with moderate to severe disease
Joyner 2020
  35,322 (20,000 included in safety analysis) Total events within 7 days after transfusion: 1282
Within 4 h after transfusion: 146 events reported

  • 63 dead (12 possibly, 1 probably, 0 definitely related)

  • 37 TACO (37 potentially, probably, or definitely related)

  • 20 TRALI (20 potentially, probably, or definitely related)

  • 26 severe allergic reaction (26 potentially, probably, or definitely related)


Within 7 days after transfusion: additional 1136 events reported

  • 87 thrombotic or thromboembolic complication (32 potentially, probably, or definitely related)

  • 406 sustained hypotension (54 potentially, probably, or definitely related)

  • 643 cardiac events (74 potentially, probably, or definitely related)

 N/A (single‐arm study)
 
       
Convalescent plasma versus placebo or standard of care alone for individuals with mild disease  
Libster 2020 80 in CP group and 80 in control group

  • 0 individuals with solicited adverse events

  • 0 individuals with solicited adverse events

Abbreviations: CP: convalescent plasma; NR: not reported; TACO: transfusion‐associated circulatory overload; TRALI: transfusion‐related acute lung injury; SAEs: serious adverse events; SHOT: serious hazards of transfusion.